目的:目前溃疡性结肠炎(UC)的药物治疗有局限性。因此,阐明任何可用的替代或补充治疗是很重要的,中草药显示出这种治疗的潜力。作为一种传统的中草药,据报道,丹参相关制剂通过改善凝血功能和抑制炎症反应对UC有益。尽管如此,这种做法的可信度和安全性是不完整的。因此,为了探讨丹参制剂(DSP)治疗UC的有效性和安全性,我们进行了系统评价和荟萃分析.方法:PubMed,Embase,科克伦图书馆,WebofScience,中国国家知识基础设施,本综述检索万方数据库和CQVIP数据库。主要观察指标为DSP联合美沙拉嗪或DSP对有效率的影响,血小板计数(PLT),UC患者的平均血小板体积(MPV)和C反应蛋白(CRP)。使用Cochrane偏倚风险工具评估偏倚风险。使用RevMan5.4和Stata17.0软件对所选研究的质量和数据处理进行评估。结果:共纳入37项研究。其中,纳入了26项临床试验,包括2426名患者,并纳入了11项动物实验研究,涉及208只动物。Meta分析结果显示,与单独使用美沙拉嗪相比,联合使用DSP可以明显提高临床有效率(RR0.86%,UC的95%CI:0.83-0.88,p<0.00001)。此外,它通过降低血清PLT和增加MPV水平来改善凝血功能,通过降低血清CRP控制炎症反应,TNF-α,患者的IL-6和IL-8水平。结论:DSP联合美沙拉嗪治疗UC可提高临床疗效。然而,由于本次审查的缺陷,在解释其结果时应谨慎行事,例如,由于研究盲而导致的分配隐藏和不确定性。系统审查注册:http://www。crd.约克。AC.英国/PROSPERO/myprospro.php,标识符PROSPERO:CRD42022293287。
Purpose: Current pharmacological treatments for Ulcerative Colitis (UC) have limitations. Therefore, it is important to elucidate any available alternative or complementary treatment, and Chinese herbal medicine shows the potential for such treatment. As a traditional Chinese herbal medicine, Danshen-related preparations have been reported to be beneficial for UC by improving coagulation function and inhibiting inflammatory responses. In spite of this, the credibility and safety of this practice are incomplete. Therefore, in order to investigate whether Danshen preparation (DSP) is effective and safe in the treatment of UC, we conducted a systematic review and meta-analysis. Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Database and CQVIP Database were searched for this review.The main observation indexes were the effect of DSP combined with
mesalazine or DSP on the effective rate, platelet count (PLT), mean platelet volume (MPV) and C-reactive protein (CRP) of UC. The Cochrane risk of bias tool was used to assess the risk of bias. The selected studies were evaluated for quality and data processing using RevMan5.4 and Stata17.0 software. Results: A total of 37 studies were included. Among them, 26 clinical trials with 2426 patients were included and 11 animal experimental studies involving 208 animals were included. Meta-analysis results showed that compared with
mesalazine alone, combined use of DSP can clearly improve the clinical effective rate (RR 0.86%, 95% CI:0.83-0.88, p < 0.00001) of UC. Furthermore it improved blood coagulation function by decreasing serum PLT and increasing MPV levels, and controlled inflammatory responses by reducing serum CRP, TNF-α, IL-6, and IL-8 levels in patients. Conclusion: Combining DSP with
mesalazine for UC can enhance clinical efficacy. However, caution should be exercised in interpreting the results of this review due to its flaws, such as allocation concealment and uncertainty resulting from the blinding of the study. Systematic Review Registration: http://www.crd.york.ac.uk/PROSPERO/myprospero.php, identifier PROSPERO: CRD42022293287.